Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
Kailera · Obesity · Overweight
Phase 2
Recruiting
320
2026-07
Industry sponsor intelligence
KaileraClinical Pipeline.
Lead-sponsor view of Kailera's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 5
- Recruiting
- 4
- Active
- 1
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 1,056
Pipeline overview
Programs by phase and activity.
Velocity
Kailera trials by start year
Study start year · indexed snapshot
Development
Trials by phase
5phase labels
Early Phase 10
Phase 10
Phase 22
Phase 33
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Glucagon → | 5 | 0 | 2 | 3 | 0 | 5 |
| Semaglutide → | 1 | 0 | 0 | 1 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Kailera · Obesity · Overweight
Phase 3
Recruiting
2,340
2026-07
Phase 3
Recruiting
1,200
2026-07
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Kailera · Obesity With Diabetes · Overweight With Diabetes
Phase 3
Recruiting
1,156
2026-07
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
Kailera · Obesity
Phase 2
Active, not recruiting
264
2026-07
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All Kailera studies.
This page groups studies where Kailera is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
5 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT07497880Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related ComorbidityJul 28, 2026NCT07284875Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have DiabetesJul 22, 2026NCT07284979Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have DiabetesJul 22, 2026NCT07284901Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and DiabetesJul 15, 2026NCT07458269Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have DiabetesJul 15, 2026